Shares of Trius Therapeutics (TSRX +5.6%) gain this morning after the company announced late yesterday that it's received a Notice of Allowance from the USPTO on an application related to its tedizolid phosphate patent portfolio. The new application protects a therapeutic combination of the experimental medicine with a currently available antibiotic daptomycin. Together, TSRX claims the medicines can prevent the development of certain strains of staph infection.
Shares of Trius Therapeutics (TSRX +5.6%) gain this morning after the company announced late...
From other sites
Video at CNBC.com (Fri, 8:13AM)
Video at CNBC.com (Fri, 7:15AM)
Video at CNBC.com (Jul 1, 2016)
Video at CNBC.com (Jun 16, 2016)
Video at CNBC.com (Jun 6, 2016)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs